Zobrazeno 1 - 10
of 151
pro vyhledávání: '"Andreas Pinter"'
Autor:
Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1575-1585 (2024)
Abstract Introduction Plaque psoriasis is a common, often debilitating, chronic autoimmune inflammatory skin disease. Moderate-to-severe forms of psoriasis can be treated with biologics such as anti-interleukin and anti-tumor necrosis factor antibodi
Externí odkaz:
https://doaj.org/article/e9b7b0657edb442485e72266f6487833
Autor:
Andreas Pinter, Ahmed M. Soliman, Irina Pivneva, Roksana Ghanbariamin, Min Yang, Bang Truong, Luis Puig, Mark Lebwohl
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1259-1271 (2024)
Abstract Introduction Real-world data on the efficacy of risankizumab (RZB) in clinical moderate-to-severe plaque psoriasis (PsO) are limited. The RAPID study assessed real-world clinical and patient-reported outcomes in RZB-treated PsO patients usin
Externí odkaz:
https://doaj.org/article/6166294923574c7eb1b770f5d1d6b0c3
Autor:
Elisabeth Riedl, Andreas Pinter, Shirin Zaheri, Antonio Costanzo, Alan Brnabic, Bruce Konicek, Robert McKenzie, Anastasia Lampropoulou, Mohamed El Rayes, Natalie Haustrup, Christopher Schuster
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1327-1335 (2024)
Abstract Introduction Nail psoriasis is highly prevalent among patients with psoriasis yet remains one of the most challenging areas to treat. To better understand the treatment landscape for psoriatic nail disease, more studies are needed that compa
Externí odkaz:
https://doaj.org/article/a3b1f7dde7b6448eae9fbfb2225da04b
Autor:
Iris Verbinnen, Emilio Monte-Boquet, Detlev Parow, Fabienne Lacombe, Andrew Pothecary, Arno W. R. van Kuijk, Laura Harrington, Edita Müllerová, Andreas Pinter, Ulrike Erstling, Andrea Tomasini, Philip S. Helliwell
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 795-815 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a complex, progressive, and often debilitating disease. Despite recent advances in treatment, numerous unmet needs in patient care persist. Rheumacensus is a multistakeholder, pan-European initiative
Externí odkaz:
https://doaj.org/article/177ca0c0dd2a494c9e8e59080661e07b
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 2, Pp 521-532 (2024)
Abstract Introduction Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin i
Externí odkaz:
https://doaj.org/article/27b4cef1cd53480cb6677b76c7f7188f
Autor:
Andreas Pinter, Kilian Eyerich, Antonio Costanzo, Alyssa Garrelts, Christopher Schuster, Can Mert, Anastasia Lampropoulou, Konstantinos Fotiou, Julia-Tatjana Maul, Kim A. Papp
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose Currently, in the treatment of moderate-to-severe psoriasis (PsO) there is a lack of evidence demonstrating optimal biologic treatment response with respect to disease duration. The aim of this post-hoc analysis, using real world data
Externí odkaz:
https://doaj.org/article/109029d531134ab5b27492e558a2ff92
Autor:
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, Ryuta Sakuma, Luis Puig, Matthew Davis, Dominic Nunag, Andreas Pinter, Shinichi Imafuku
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 1, Pp 99-114 (2023)
Abstract Introduction Patients with moderate-to-severe psoriasis (PsO) treated with interleukin (IL)-inhibitors may require treatment modification to achieve disease control. This study evaluated discontinuation and switching of IL-inhibitors for PsO
Externí odkaz:
https://doaj.org/article/c7c766b9c1614705a27a88d773493cf3
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in
Externí odkaz:
https://doaj.org/article/bccccf39e2c04fe797d29dddc1d7b23d
Autor:
Tiago Torres, Jordi Galván, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Paolo Gisondi, José Manuel Carrascosa, Bruno Halioua, Anthony Bewley, Andreas Pinter
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 10, Pp 2153-2169 (2023)
Abstract Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line ch
Externí odkaz:
https://doaj.org/article/b05d2962ef644edebef73ab4bc98c535
Autor:
Bruce W. Kirkham, Alexander Egeberg, Frank Behrens, Andreas Pinter, Joseph F. Merola, Thorsten Holzkämper, Gaia Gallo, Khai Jing Ng, Rebecca Bolce, Christopher Schuster, Peter Nash, Luis Puig
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 5, Pp 1127-1146 (2023)
Abstract Nail psoriasis is a difficult-to-treat manifestation of psoriatic disease affecting up to 80% of patients with psoriatic arthritis (PsA) and 40–60% of patients with plaque psoriasis (PsO). Ixekizumab (IXE), a high-affinity monoclonal antib
Externí odkaz:
https://doaj.org/article/4c9392c1257a45e0b15c5bcafb3f3df9